Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLO-Surgery: Indocyanine Green and Near-Infrared Fluorescence in Paediatric Oncology Surgery
2024-514089-37-00Phase 2Authorised
- Sponsor
- University of Birmingham
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of indocyanine green in cancer, rhabdomyosarcoma (RMS), soft tissue sarcoma (STS) and 4 more (3 cohorts), sponsored by University of Birmingham. Primary endpoint: Total number of nodes sampled (Cohorts 2 and 3). Planned start Apr 2026; status: authorised.
02
Drugs
indocyanine green
03
Conditions
cancerrhabdomyosarcoma (RMS)soft tissue sarcoma (STS)neuroblastomaGerm Cell Carcinoma
Beyond the preview
Go deeper on 2024-514089-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514089-37-00.